Strom B L, Miettinen O S, Melmon K L
Am J Med. 1984 Oct;77(4):703-8. doi: 10.1016/0002-9343(84)90369-3.
This report reviews the 100 most recently approved drugs in order to quantify the frequency with which post-marketing studies of drug efficacy can be performed experimentally and non-experimentally. These drugs represent 131 potential drug uses. Of them, the absolute efficacy of 89 (68 percent) could be evaluated from clinical observations. Of the remaining 42, six (14 percent) could be studied experimentally or non-experimentally, six (14 percent) only experimentally, one (2 percent) only non-experimentally, and 29 (69 percent) by neither technique. Answers to all questions of relative efficacy required formal research. Of these, 94 (72 percent) could be studied using either experimental or non-experimental techniques. The remaining 37 (28 percent) could be studied experimentally only. Thus, clinical observations and non-experimental research can contribute a large proportion of the information about drug efficacy still needed after marketing.
本报告回顾了最近获批的100种药物,以便量化上市后药物疗效研究通过实验性和非实验性方法开展的频率。这些药物代表了131种潜在的药物用途。其中,89种(68%)的绝对疗效可通过临床观察进行评估。其余42种中,6种(14%)可通过实验性或非实验性方法进行研究,6种(14%)仅能通过实验性方法研究,1种(2%)仅能通过非实验性方法研究,29种(69%)两种方法都无法研究。所有关于相对疗效问题的答案都需要正式研究。其中,94种(72%)可使用实验性或非实验性方法进行研究。其余37种(28%)仅能通过实验性方法研究。因此,临床观察和非实验性研究可为上市后仍需的大量药物疗效信息做出贡献。